SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential partnerships and adoption by major players. Chatter revolves around Pyth's role in the Real World Asset (RWA) space, with some speculating on future price targets. Discussions also highlight the potential impact of institutional adoption and expansion into new markets.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates a potential ETF, with many discussing key price levels and expressing bullish sentiment. Some are pointing to technical indicators suggesting a possible breakout and expressing excitement about potential gains. The broader crypto market trends and potential rate cuts are also fueling optimism.

Ainalyzr is a versatile and engaging platform designed to provide crypto traders with advanced tools and a fun, interactive environment. Powered by the Ainalyzr token, it offers real-time analysis of Solana-based tokens, gamified trading tools, and a space for users to explore market trends and make data-driven decisions. Ainalyzr merges functionality and entertainment, appealing to both seasoned and novice traders.

AInalyzr

AInalyzr ($AINAL.X) is gaining traction as the community highlights its potential for significant growth. Investors are discussing its "sleeper gem" qualities and anticipating a potential "lift off". The project's mint and association with other cryptocurrencies like Bitcoin and Solana are central to the conversation.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as community members highlight its strong chart setup, coiling pattern, and potential for a breakout. Discussions revolve around accumulation phases, steady bullish momentum, and the anticipation of a significant upward move. The community also notes growing awareness and potential partnerships, contributing to the bullish sentiment.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock price rallies, fueled by momentum in its energy business and speculation around future AI and robotics initiatives. The community is actively debating whether this surge is justified by fundamentals or driven by market manipulation, with some pointing to a potential short squeeze while others highlight concerns about insider selling and product safety. Discussions also include broader market conditions and potential impacts on the EV sector.

The ODP Corp. is a holding company, which engages in the provision of business services and supplies, products, and digital workplace technology solutions. It operates through the following segments: ODP Business Solutions Division, Office Depot Division, and Veyer Division. The ODP Business Solutions Division acts as a B2B distribution solutions provider serving small, medium, and enterprise level companies, including those in the public and education sectors. The Office Depot Division offers retail consumer and small business products and services distributed through a fully integrated omni-channel platform of 869 Office Depot and OfficeMax retail. The Veyer Division consists of supply chain, distribution, procurement, and global sourcing operation, which specializes in B2B and consumer business service delivery, with core competencies in distribution, fulfillment, transportation, global sourcing and purchasing. The company was founded in 1986 and is headquartered in Boca Raton, FL.

ODP Corporation (The)

$ODP is trending due to controversy surrounding an Office Depot refusing to print a poster, sparking outrage and calls for boycotts, drawing comparisons to Bud Light and Cracker Barrel situations.  The community is focused on the potential financial impact and debating the company's business strategy amidst political divides. Investors are also weighing upcoming earnings and recent research reports.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as the community discusses potential breakouts and compares it to other meme coins like Doge and Shib. Some users are expressing frustration with price fluctuations, while others remain optimistic about long-term gains and potential rallies. The conversation also includes mentions of potential market manipulation and the broader meme coin sector.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending as traders anticipate Phase 3 EFZO-FIT data, expected mid-September, focusing on pulmonary sarcoidosis treatment. The community is actively discussing aggressive ask-side put sweeps, high implied volatility, and potential binary gap risk, while also debating the significance of recent analyst ratings and commercial hires. Some traders are weighing defined-risk setups and hedging strategies amid the uncertainty.

Trump For President

The TRUMP.X crypto is trending amid discussions about a potential ETF and its correlation with other cryptos like BTC and ETH. Community members are debating its future value, especially if Trump actively supports or acknowledges the coin, while also commenting on his recent summit with Putin. Political opinions and sentiments toward Trump are heavily influencing the conversation around this speculative asset.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

$KENDU.X is trending due to its strong community and ongoing efforts to build real-world utility, including businesses and events, with community members highlighting its dedication to growth. Despite some market downturns, the community remains highly engaged, actively promoting the brand and expressing excitement for future developments. The community is currently discussing its unique brandcoin model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Travere Therapeutics (TVTX) on Wednesday said that the U.S. Food and Drug Administration informed the company that it has waived the need for an advisory committee meeting regarding its application for Filspari in treating focal segmental glomerulosclerosis (FSGS).The FDA is expected to decide on the company’s application by January 13, 2026. If approved, Filspari would be the first medication indicated for FSGS, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250910301976/en/Travere-Therapeutics-Provides-Update-on-FDA-Advisory-Committee-Meeting-for-FILSPARI-sparsentan-in-FSGS">said</a>. FSGS is a rare and serious kidney disorder driven by proteinuria or protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. The disease leads to progressive kidney function loss and kidney failure and is estimated to affect more than 40,000 patients in the U.S., according to Travere. &nbsp;Shares of the company soared 16% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TVTX">TVTX stock</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.CEO Eric Dube said that the company is pleased with the progress of its new application for Filspari to date and is continuing preparation for a successful commercial launch in January, if approved.The company’s application is supported by data from mid-stage and late-stage studies where Filspari demonstrated rapid, superior, and sustained reductions in proteinuria when compared with the maximum labeled dose of the approved drug Irbesartan across adult and pediatric patients. The drug was also well-tolerated in the studies with a safety profile comparable to Irbesartan.Filspari is already approved by the FDA to slow kidney function decline in adults with IgA nephropathy, a chronic autoimmune kidney disease characterized by the abnormal accumulation of immunoglobulin A (IgA) antibodies in the kidneys' filtering units. The new application by the company seeks to expand its use to the treatment of FSGS as well.TVTX stock is up by 24% this year and by about 69% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-stock-rises-pre-market-after-company-announces-positive-efficacy-data-for-agitation-drug-in-study/chwk7aERdub">BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application

If approved, Filspari would be the first medication indicated for focal segmental glomerulosclerosis, a rare and serious kidney disorder driven by proteinuria, the company said. 

Equity

If approved, Filspari would be the first medication indicated for focal segmental glomerulosclerosis, a rare and serious kidney disorder driven by proteinuria, the company said. 


Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of +50.00% and +17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics shares tumbled over 15% in extended trading Thursday after the company said the U.S. Food and Drug Administration will convene an advisory committee meeting to review a supplemental use of its kidney drug, Filspari.The FDA accepted Travere's supplemental New Drug Application (sNDA) seeking traditional approval of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tvtx-stock-soars-on-fda-approval-plan-for-filspari/ch57VA1RMt">Filspari</a> for the treatment of focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disorder with no FDA-approved therapies.&nbsp;Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026."We are one step closer to potentially delivering the first approved treatment for people living with FSGS - a leading cause of kidney failure and devastating condition that urgently needs new treatment options," said CEO Eric Dube.While the advisory committee (AdComm) meeting introduces an added review step, it is a standard part of the FDA's drug approval process and not necessarily a red flag. However, negative recommendations from such meetings can lead to delays or rejections.Despite the market reaction, sentiment on Stocktwits ended 'extremely bullish' on Thursday, with message volume jumping from 'normal' to 'high.' Some retail traders saw the selloff as overdone.<figure class="image"><img style="aspect-ratio:1318/192;" src="https://news.stocktwits-cdn.com/TVTX_sentiment_and_message_volume_as_of_May_15_png_4829a2c988.webp" alt="TVTX sentiment and message volume as of May 15.png" width="1318" height="192"><figcaption>TVTX sentiment and message volume as of May 15. | source: Stocktwits</figcaption></figure>"Oversold now.&nbsp; It's an ADCOM, and by no means a bad thing when a meeting is required. It boils down to a safe and highly needed prescription drug, that just needs to thread the needle of the FDA," one user wrote.<stembedurl>https://stocktwits.com/FloatTrip/message/614839023</stembedurl>"From late fall to just January 2026, is not that big of a deal to wait to get the "T's" crossed and the "I's" dotted. A few months added from the original timeframe," another said, brushing off the timeline shift.<stembedurl>https://stocktwits.com/FloatTrip/message/614836495</stembedurl>However, investors often cheer when the FDA skips an AdComm — as seen in March, when Tonix Pharma stock surged on news its fibromyalgia drug would not require such a review.Filspari is already approved to slow kidney function decline in IgA nephropathy, another rare kidney condition. FSGS affects more than 40,000 patients in the U.S., and Travere is seeking to expand Filspari's label for this population.<a href="https://stocktwits.com/symbol/TVTX">Travere shares</a> are up over 19% year to date, but short interest has climbed, rising from 8.5% at the start of 2025 to 11.9% as of last week, according to Koyfin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chronic kidney disease, computer illustration and light micrograph. The illustration shows the gross anatomy of kidneys with chronic glomerulonephritis. | Image source: Getty Images

Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries

Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026.

Shares of Travere Therapeutics Inc. surged over 13% Tuesday afternoon, reaching their highest level since October 2022 and driving a spike in retail discussions on Stocktwits.The rally followed Travere’s announcement that it plans to seek full FDA approval for Filspari in treating focal segmental glomerulosclerosis (FSGS), a rare kidney disorder.&nbsp;The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.According to The Fly, Wells Fargo sees the accelerated timeline as a strong positive. It estimates a 60%- 70% probability of success, which it models as a fair value range of $27-$30 per share.&nbsp;At full approval, the firm values the stock at $40 per share, but currently maintains an ‘Overweight’ rating with a $27 price target.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TVTX_sentiment_and_message_volume_Feb_11_40f540ed9b.png" alt="TVTX sentiment and message volume Feb 11.png" width="1318" height="324"><figcaption>TVTX sentiment and message volume Feb 11 as of 1:20 pm ET | source: Stocktwits</figcaption></figure>Stocktwits sentiment for Travere turned ‘bullish,’ with message volume (81/100) hitting a three-month high.&nbsp;Retail traders cheered the news, with some analyzing technical patterns signaling further gains.&nbsp;<stembedurl>https://stocktwits.com/Frostblade91/message/603708895</stembedurl><stembedurl>https://stocktwits.com/RonIsWrong/message/603732744</stembedurl>FSGS is a rare kidney disorder affecting over 40,000 patients in the U.S., with no current FDA-approved treatments.&nbsp;Filspari has already been approved to slow kidney function decline in adults with IgA nephropathy.Shares of Travere have nearly tripled over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug

The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.27	--	--	N/A
Q2 '25	-$0.31	-$0.14	55.08%	BEAT
Q1 '25	-$0.57	-$0.47	17.11%	BEAT
Q4 '24	-$0.56	-$0.73	-29.89%	MISSED
Q3 '24	-$0.64	-$0.70	-9.39%	MISSED

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest TVTX News

TVTX Travere Therapeutics Inc